Current Headlines
-
AI Speeds Up Drug Design For Parkinson’s Ten-Fold
4/17/2024
The researchers, from the University of Cambridge, designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson’s.
-
A New Generation Of Antidepressant Drug Precision Treatment Based On Revolutionary AI Technology Is Born
4/17/2024
The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that its investee WM Therapeutics Co., Ltd. (未名脑脑) ("WM Therapeutics") has achieved revolutionary breakthroughs in the proprietarily developed research and development of antidepressant drug precision treatment.
-
CureVac And MD Anderson Enter Strategic Collaboration To Develop Novel Cancer Vaccines
4/16/2024
CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
-
Improving Drug Development With A Vast Map Of The Immune System
4/11/2024
The human immune system is a network made up of trillions of cells that are constantly circulating throughout the body.
-
Scripps Research Chemists Devise Easier New Method For Making A Common Type Of Building Block For Drugs
4/11/2024
Ring-shaped chemical structures called saturated heterocycles are found in most FDA-approved drugs but are often difficult to create. Scripps Research chemists have just developed a surprisingly easy method for making many of these sought-after compounds from inexpensive starting chemicals.
-
Scientists Find New Ways To Convert Inhibitors Into Degraders, Paving The Way For Future Drug Discoveries
4/11/2024
Researchers have discovered ways to convert inhibitor-style targeted cancer drugs into small molecules known as degraders, which help destroy cancer-promoting proteins in cells.
-
Global Collaboration To Combat Chronic Lung Infection
4/10/2024
Scientists have discovered a target for the development of a drug to combat a bacterium that can cause chronic lung infection in hospitalised patients, immunocompromised individuals and people with cystic fibrosis.
-
Tr1X Announces FDA Clearance Of First Investigational New Drug Application For TRX103, An Allogeneic Regulatory T-Cell Therapy To Treat Autoimmune Diseases
4/10/2024
Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the development of novel allogeneic regulatory T cell therapies (Allo-Tregs) and allogeneic regulatory T cells expressing Chimeric Antigen Receptors (Allo-CAR Tregs), today announced the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT).
-
BioCity Announces FDA Clearance Of The Investigational New Drug Application For Its First-In-Class Antibody Drug Conjugate Targeting Glypican 3
4/9/2024
BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (ADC) approved for clinical development, targets Glypican 3 (GPC3), a proteoglycan found in the outer membrane of cancer cells.
-
Sartorius And TheWell Bioscience Partner To Enable More Accurate Predictions In Drug Discovery
4/9/2024
The life science group Sartorius and U.S.-based startup TheWell Bioscience have agreed to partner on the further development of hydrogels and bioinks tailored to produce 3D advanced cell models for drug discovery workflows.